Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
about
Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms.NLR-regulated pathways in cancer: opportunities and obstacles for therapeutic interventions.Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes.
P2860
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
@en
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
@nl
type
label
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
@en
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
@nl
prefLabel
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
@en
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
@nl
P2860
P356
P1476
Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
@en
P2093
Eugen Dhimolea
P2860
P356
10.2147/TACG.S8146
P577
2011-01-26T00:00:00Z